Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-22T08:27:47.992Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacology of 5-HT1A Receptors: Critical Aspects

Published online by Cambridge University Press:  07 November 2014

Franco Borsini
Get access Rights & Permissions [Opens in a new window]

Abstract

Myriad difficulties exist in analyzing the pharmacology of the serotonin 1A (5-HT1A) receptor. The receptor may demonstrate a different activity depending on the tissue or species used for analysis, the agent used, laboratory conditions, and differences between in vitro and in vivo effects of compounds. Affinity for 5-HT receptors also varies widely, presenting difficulties in drawing definitive conclusions on affinity values for various compounds. At least two possibilities exist to explain the diversity of pharmacology of 5-HT receptors. First, it is possible that different 5-HT1A receptor subtypes exist. Second, the 5-HT1A receptors may play a far more complex role than previously believed.

Type
Feature Articles
Information
CNS Spectrums , Volume 3 , Issue 10 , December 1998 , pp. 17 - 38
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Kobilka, BK, Frielle, T, Collins, S, et al.An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature. 1987;329:75–79.Google Scholar
2.Fujiwara, Y, Nelson, DL, Kashihara, K, et al.The cloning and sequence analysis of the rat serotonin-1A receptor gene. Life Sci. 1990;47:127–132.Google Scholar
3.Albert, PR, Zhou, QY, vanTol, HHM, et al.Cloning, functional expression, and mRNA tissue distribution of the rat-hydroxytryptamime1A receptor gene. J Biol Chem. 1990;265:5825–5832.Google Scholar
4.Fujiwara, Y, Tomita, H, Hikiji, M, et al.Characterization of a cloned rat serotonin 5-HT1A receptor expressed in the HeLa cell line. Life Sci. 1993;52:949–958.Google Scholar
5.Fargin, A, Raymond, JR, Lohsa, MJ, et al.The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature. 1988;335:358–360:Google Scholar
6.Stam, NJ, van Huizen, F, van Alebeek, C, et al.Genomic organization, coding sequence and functional expression of human 5-HT2 and 5-HT1A receptor genes. Eur J Pharmacol. 1992;227:153–162.Google Scholar
7.Marazziti, D, Marracci, S, Palego, L, et al.Localization and gene expression of serotonin 1A (5HT1A) receptors in human brain postmortem. Brain Res. 1994;658:55–59.Google Scholar
8.Boess, FG, Martin, IL. Molecular biology of 5-HT receptors. Neuropharmacology. 1994;33:275–317.Google Scholar
9.Hall, MD, El Mestikawy, S, Emerit, MB, et al.[3H]8-hydroxy-2-(di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain. J Neurochem. 1985;44:1685–1696.Google Scholar
10.Zifa, E, Fillion, G. 5-Hydroxytryptamine receptors. Pharmacol Rev. 1992;44:401–458.Google Scholar
11.Pauwels, P, van Gompel, P, Leysen, JE. Activity of serotonin (5-HT) receptor agonists, partial agonists and antagonists at cloned human 5-HT1A receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa cells. Biochem Pharmacol. 1993;45:375–383.CrossRefGoogle ScholarPubMed
12.Raymond, JR, Albers, FJ, Middleton, JP. Functional expression of human 5-HT1A receptors and differential coupling to second messengers in CHO cells. Naunyn-Schmiedebergs Arch Pharmacol. 1992;346:127–137.Google Scholar
13.Raymond, JR, Olsen, CL, Gettys, TW. Cell-specific physical and functional coupling of human 5-HT1A receptors to inhibitory G protein alpha-subunits and lack of coupling to Gsalpha. Biochemistry. 1993;32:11064–11073.Google Scholar
14.De Vivo, M, Maayani, S. Characterization of the 5-hydroxytryptaminelA receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. J Pharmacol Exp Ther. 1986;238:248–253.Google Scholar
15.Blier, P, Lista, A, De Montigny, C. Differential properties of pre- and postsynaptic 5-hydroxytryptamine1A receptors in the dorsal raphe and hippocampus: II. Effect of pertussis and cholera toxins. J Pharmacol Exp Ther. 1993;265:16–23.Google Scholar
16.Markstein, R, Hoyer, D, Engel, G. 5-HT1A receptor mediated stimulation of adenylate cyclase in rat hippocampus. Naunyn-Schmiedebergs Arch Pharmacol. 1986;333:335–341.Google Scholar
17.Shenker, A, Maayani, S, Weinstein, H, Green, JP. Pharmacological characterization of two 5-hydroxytryptamine receptors coupled to adenylate cyclase in guinea pig hippocampal membranes. Mol Pharmacol. 1987;31:357–367.Google Scholar
18.Clarke, WP, Yocca, FD, Maayani, S. Lack of 5-hydroxy-tryptamine1A-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats. J Pharmacol Exp Ther. 1996;277:1259–1266.Google Scholar
19.Andrade, R, Malenka, RC, Nicoll, RA. A G protein couples serotonin and GABA-B receptors to the same channels in hippocampus. Science. 1986;234:1261–1265.CrossRefGoogle Scholar
20.Larkman, PM. Electrophysiological aspects of 5-HT receptor-mediated adenylyl cyclase activation. Seminars in the Neurosciences. 1995;7:383–393.Google Scholar
21.Claustre, Y, Benavides, J, Scatton, B. Potential mechanisms involved in the negative coupling between serotonin 5-HT1A receptors and carbachol-stimulated phosphoinositide turnover in rat hippocampus. J Neurochem. 1991;56:1276–1285.Google Scholar
22.Samochocki, M, Strosnajder, J. The negative coupling between serotonin and muscarinic receptor(s) for arachidonic acid and inositol phosphates release in brain cortex synaptoneurosomes: effect of aging. Neurochem Int. 1995;26:571–578.Google Scholar
23.Stroznajder, J, Chalimoniux, M, Samochocki, M. Activation of serotonergic 5-HT1A receptor reduces Ca2+- and glutamatergic receptor-evoked arachidonic acid and No/cGMP release in adult hippocampus. Neurochem Int. 1996;28:439–444.Google Scholar
24.Johnson, RG, Fiorella, D, Winter, JC, Rabin, RA. [3H]8-OH-DPAT labels a 5-HT site coupled to inhibition of phosphoinositide hydrolysis in the dorsal raphe. Eur J Pharmacol. 1997;329:99–106.Google Scholar
25.Lembo, PMC, Albert, PR. Multiple phosphorylation sites are required for pathway-selective uncoupling of the 5-hydroxytryptamine1A receptor by protein kinase C. Mol Pharmacol. 1995;48:1024–1029.Google Scholar
26.Gettys, TW, Fields, TA, Raymond, JR. Selective activation of inhibitory G-protein alpha-subunits by partial agonists of the human 5-HT1A receptor. Biochemistry. 1994;33:4283–4290.CrossRefGoogle ScholarPubMed
27.Schoeffter, P, Fozard, JR, Stoll, A, et al.SDZ 216-525, a selective and potent 5-HT1A receptor antagonist. Eur J Pharmacol. 1993;244:251–257.Google Scholar
28.Varrault, A, Journot, L, Audigier, Y, Bockaert, J. Transfection of human 5-HT1A receptors in NIH-3T3 fibroblasts: effects of increasing receptor density on the coupling of 5-hydroxytryptamine1A receptors to adeny-lyl cyclase. Mol Pharmacol. 1992;41:999–1007.Google Scholar
29.DeVivo, M, Maayani, S. Stimulation and inhibition of adenylyl cyclase by distinct-hydroxytryptamine receptors. Biochem Pharmacol. 1990;40:1551–1558.Google Scholar
30.Varrault, A, Bockaert, J. Differential coupling of 5-HT1A receptors occupied by 5-HT or 8-OH-DPAT to adenylyl cyclase. Naunyn-Schmiedebergs Arch Pharmacol. 1992;346:367–374.Google Scholar
31.Beck, SG, Choi, KC, List, TJ. Comparison of 5-hydroxy-tryptamine1A-mediated hyperpolarization in CA1 and CA3 hippocampal pyramidal cells. J Pharmacol Exp Ther. 1992;263:350–359.Google Scholar
32.Done, CJG, Sharp, T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology. 1994;33:411–421.Google Scholar
33.Cadogan, AK, Kendall, DA, Marsden, CA. Serotonin 5-HT1A receptor activation increases cyclic AMP formation in the rat hippocampus in vivo. J Neurochem. 1994;62:1816–1821.Google Scholar
34.Sijbesma, H, Schipper, J, Molewijk, HE, et al.8-Hydroxy-2-(di-n-propylamino)tetralin increases the activity of adenylate cyclase in the hippocampus of freely-moving rats. Neuropharmacology. 1991;30:967–975.Google Scholar
35.Blier, P, de Montigny, C, Tardif, D. Short-term lithium treatment enhances responsiveness of postsynaptic 5-HT1A receptors without altering 5-HT autoreceptor sensitivity: an electrophysiological study in the rat brain. Synapse. 1987;1:225–232.Google Scholar
36.Blier, P, de Montigny, C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse. 1987;1:470–480.Google Scholar
37.Ceci, A, Baschirotto, A, Borsini, F. The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesions of the frontal cortex. Neuropharmacology. 1994;33:709–713.Google Scholar
38.Bosker, F, Vrinten, D, Klompmakers, A, Westenberg, H. The effects of a 5-HT1A receptor agonist and antagonist on the 5-hydroxytryptamine release in the central nucleus of the amygdala: a microdialysis study with flesinoxan and WAY 100635. Naunyn-Schmiedebergs Arch Pharmacol. 1997;355:347–353.Google Scholar
39.Hjorth, S, Suchowski, CS, Galloway, MP. Evidence for 5-HT autoreceptor-raediated, nerve impulse-independent, control of 5-HT synthesis in the rat brain. Synapse. 1995;19:170–176.Google Scholar
40.Ahlenius, S, Hillegaart, V, Wijkstrom, A. Evidence for selective inhibition of limbic forebrain dopamine synthesis by 8-OH-DPAT in the rat. Naunyn-Schmiedebergs Arch Pharmacol. 1989;339:551–556.Google Scholar
41.Hamon, M, Fattaccini, CM, Adriun, J, et al.Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptaminelA agonists with potential anxiolytic properties. J Pharmacol Exp Ther. 1988;246:745–752.Google Scholar
42.Ahlenius, S, Hillegaart, V, Wijkstrom, A. Increased dopamine turnover in the ventral striatum by 8-OH-DPAT administration in the rat. J Pharm Pharmacol. 1990;42:285–288.Google Scholar
43.Arborelius, L, Nomikos, GG, Hacksell, U, Svensson, TH. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand. 1993;148:465–466.Google Scholar
44.Benloucif, S, Galloway, MP. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol. 1991;200:1–8.Google Scholar
45.Arborelius, L, Chergui, K, Murase, S, et al.The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedebergs Arch Pharmacol. 1993;347:353–362.Google Scholar
46.Hajos-Korcsok, E, Sharp, T. 8-OH-DPAT-induced release of hippocampal noradrenaline in vivo: evidence for a role of both 5-HT1A and dopamine D1 receptors. Eur J Pharmacol. 1996;314:285–291.Google Scholar
47.Suzuki, M, Matsuda, T, Asano, S, et al.Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine1A receptor activation. Br J Pharmacol. 1995;115:703–711.Google Scholar
48.Bianchi, C, Siniscalchi, A, Beani, L. 5-HT1A agonists increase and 5-HTg agonists decrease acetylcholine efflux from the cerebral cortex of freely-moving guineapigs. Br J Pharmacol. 1990;101:448–452.Google Scholar
49.Fujii, T, Yoshizawa, M, Nakai, K, et al.Demonstration of the facilitatory role of 8-OH-DPAT on cholinergic transmission in the rat hippocampus using in vivo microdialysis. Brain Res. 1997;761:244–249.Google Scholar
50.Consolo, S, Ramponi, S, Ladinksy, H, Baldi, G. A critical role for D1 receptors in the 5-HT1A-mediated facilitation of in vivo acetylcholine release in rat frontal cortex. Brain Res. 1996;707:320–323.Google Scholar
51.Izumi, J, Washizuka, M, Miura, N, Hiruaga, Y, Ikeda, Y. Hippocampal serotonin 5-HT1A receptor enhances acetylcholine release in conscious rats. J Neurochem. 1994;62:1804–1808.Google Scholar
52.Matsuyama, S, Nei, K, Tanaka, C. Regulation of GABA release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus. Brain Res. 1997;761:105–112.Google Scholar
53.Gobert, A, Lejeune, F, Rivet, JM, et al.Modulation of the activity of central serotonergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats. J Pharmacol Exp Ther. 1995;273:1032–1046.Google Scholar
54.Assié, MB, Koek, W. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY 100135, but not WAY 100635, has partial agonist properties. Eur J Pharmacol. 1996;304:15–21.Google Scholar
55.Matsuda, T, Yoshikawa, T, Suzuki, M, et al.Novel benzodioxan derivative, 5-(3-[((2S)-1,4-benzodioxan-2-yhnethyl)amino]propoxy)-1,3-benzodioxole HCl (MKC-242), with a highly potent and selective agonist activity at rat central setotonin1A receptors. Jpn J Pharmacol. 1995;69:357–366.Google Scholar
56.Casanovas, JM, Artigas, F. Differential effects of ipsapirone on 5-hydroxytryptamine release in the dorsal and median raphe neuronal pathways. J Neurochem. 1996;67:1945–1952.Google Scholar
57.Casanovas, JM, Lesourd, M, Artigas, F. The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain. Br J Pharmacol. 1997;122:733–741.Google Scholar
58.Gartside, SE, Cowen, PJ, Hjorth, S. Effects of MDL 73005 EF on central pre- and postsynaptic 5-HT1A receptor function in the rat in vivo. Eur J Pharmacol. 1990;191:391–400.Google Scholar
59.Meller, E, Goldstein, M, Bohmaker, K. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists. Mol Pharmacol. 1990;37:231–237.Google Scholar
60.Routledge, C, Hartley, J, Gurling, J, et al.In vivo characterization of the putative 5-HT1A receptor antagonist SDZ 216,525 using two models of somatodendritic 5-HT1A receptor function. Neuropharmacology. 1994;33:359–366.Google Scholar
61.Routledge, C, Gurling, J, Ashworth, MA, Dourish, CT. Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190. Eur J Pharmacol. 1995;276:281–284.Google Scholar
62.Sharp, T, McQuade, R, Bramwell, S, Hjorth, S. Effect of acute and repeated administration of 5-HT1A receptor agonists on 5-HT release in rat brain in vivo. Naunyn-Schmiedebergs Arch Pharmacol. 1993;348:339–346.CrossRefGoogle ScholarPubMed
63.De Vry, J. 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology. 1995;121:1–26.Google Scholar
64.Glennon, RA. Serotonin receptors: clinical implications. Neurosci Biobehav Rev. 1990;14:35–47.Google Scholar
65.Sanchez, C. 5-HT1A receptors play an important role in modulation of behaviour of rats in a two-compartment black and white box. Behav Pharmacol. 1996;7:788–797.Google Scholar
66.Goodwin, GM, Green, AR. A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol. 1985;84:743–753.Google Scholar
67.Goodwin, GM, De Souza, R, Green, AR. The pharmacology of hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT): a model of presynaptic 5-HT1 function. Neuropharmacology. 1985;24:1187–1185.Google Scholar
68.Borsini, F, Brambilla, A, Ceci, A, et al.Flibanserin. Drugs of the Future. 1998;23:9–16.Google Scholar
69.Scott, PA, Chou, JM, Tang, H, Frazer, A. Differential induction of 5-HT1A-mediated responses in vivo by three chemically dissimilar 5-HT1A agonists. J Pharamacol Exp Ther. 1994;270:198–208.Google Scholar
70.Aulakh, CS, Wozniak, KM, Haas, M, et al.Food intake, neuroendocrine and temperature effects of 8-OH-DPAT in rat. Eur J Pharmacol. 1998;146:253–259.Google Scholar
71.Meltzer, HY, Maes, M. Effect of pindolol on hormone secretion and body temperature: partial agonist effects. J Neural Transm. 1996;103:77–88.CrossRefGoogle ScholarPubMed
72.Marracci, S, Cini, D, Nardi, I. Cloning and developmental expression of 5-HT1A receptor gene in Xenopus laevis. Brain Res Mol Brain Res. 1997;47:67–77.Google Scholar
73.Tilakaratne, N, Friedman, E. Genomic responses to 5-HT1A or 5-HT2A/2C receptor activation is differentially regulated in four regions of rat brain. Eur J Pharmacol. 1996;307:211–217.Google Scholar
74.Burnet, PWJ, Eastwood, SL, Harrison, PJ. The serotonin (5-HT1A) receptor is encoded by two mRNA species in fetal and adult human brain. Abstracts of the Society for Neuroscience. 1997;23:116–124.Google Scholar
75.Anthony, TE, Azmitia, EC. Molecular characterization of antipeptide antibodies against the 5-HT1A receptor: evi-dence for state-dependent antibody binding. Brain Res Mol Brain Res. 1997;50:277–284.Google Scholar
76.Azmitia, EC, Gannon, PJ, Kheck, NM, Whitaker-Azmitia, PM. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology. 1996;14:36–46.Google Scholar
77.Li, Q, Muma, NA, van der Kar, LD. Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine response to a 5-HT1A agonist. J Pharmacol Exp Ther. 1996;279:1035–1042.Google Scholar
78.Neonenè, EK, Radja, F, Carli, F, et al.Alkylation of [3H]8-OH-DPAT binding sites in rat cerebral cortex and hippocampus. Neurochem Res. 1996;21:167–176.Google Scholar
79.Pou, C, Neonenéx, EK, Reader, TA, Fargin, A. The human 5-HT1A receptor: comparison of its binding properties in transfected cells and cortical tissue. Gen Pharmacol. 1997;29:737–747.Google Scholar
80.Lima, L, Laporte, AM, Gaymard, M, et al.Atypical in vitro and in vivo binding of [3H]S-14506 to brain 5-HT1A receptors. J Neural Transm. 1997;104:1059–1075.Google Scholar
81.Fabre, V, Boni, C, Mocaer, E, Lesourd, M, Hamon, M, Laporte, AM. [3H]Alnespirone—a novel specific readioligand of 5-HT1A receptors in the rat brain. Eur J Pharmacol. 1997;337:297–308.Google Scholar
82.Fletcher, A, Cliffe, IA, Dourish, CT. Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol Sci. 1993;14:441–448.Google Scholar
83.Jolas, T, Haj-Dahmane, S, Kidd, EJ, et al.Central pre- and postsynaptic 5-HT1A receptors in rats treated chronically with a novel antidepressant, cericlamine. J Pharmacol Exp Ther. 1994;268:1432–1443.Google ScholarPubMed
84.Luscombe, GP, Martin, KF, Martin, LJ, et al.Medication of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors. Br J Pharmacol. 1993;108:669–677.Google Scholar
85.Blier, P, Lista, A, De Montigny, C. Differential properties of pre- and postsynaptic 5-hydroxytryptamine 1A receptors in the dorsal raphe and hippocampus: I. Effect of spiperone. J Pharmacol Exp Ther. 1993;265:7–15.Google Scholar
86.Przegalinski, E, Isamil, AM, Chojnacka-Wojcik, E, et al.The behavioural, but not the hypothermic or corticosterone, response to 8-hydroxy-2-(di-n-propylamino)tetralin, is antagonized by NAN-190 in the rat. Neuropharmacology. 1990;29:521–526.Google Scholar
87.Sanchez, C, Arnt, J, Moltzen, E. Assessment of relative efficacies of 5-HT1A receptor ligands by means of in vivo animal models. Eur J Pharmacol. 1996;315:245–254.Google Scholar
88.Blier, P, De Montigny, C. Differential effect of gepirone on presynaptic serotonin receptors: single-cell recording studies. J Clin Psychopharmacol. 1990;10:13–20.Google Scholar
89.El Mansari, M, Blier, P. In vivo electrophysiological characterization of 5-HT receptors in the guinea pig head of caudate nucleus and orbitofrontal cortex. Neuropharmacology. 1997;36:577–588.Google Scholar
90.Newman-Tancredi, A, Conte, C, Chaput, C, et al.Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor: G-protein stoichiometry. Neuropharmacology. 1997;36:451–459.Google Scholar
91.Newman-Tancredi, A, Conte, C, Chaput, C, Spedding, M, Millan, MJ. Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral agonist, WAY 100,635. Br J Pharmacol. 1997;120:737–739.Google Scholar
92.Pauwels, PJ, Tardif, S, Wurch, T, Colpaert, FC. Stimulated [S]GTPγS binding by 5-HT1A receptor agonists in recombinant cell lines: modulation of apparent efficacy by G protein activation state. Naunyn-Schmiedebergs Arch Pharmacol. 1997;356:551–561.Google Scholar
93.Stanton, JA, Beer, MS. Characterization of a cloned human 5-HT1A receptor line using [35S]GTPγS binding. Eur J Pharmacol. 1997;230:267–275.Google Scholar
94.Meltzer, HY, Maes, M. Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Biol Psychiatry. 1995;38:310–318.Google Scholar
95.Nakhai, B, Nielsen, DA, Linnoila, M, Goldman, D. Two naturally occurring amino acid substitutions in the human 5-HT1A receptor: glycine 22 to serine 22 and isoleucine 28 to valine 28. Biochem Biophys Res Commun. 1995;210:530–536.Google Scholar
96.Rotondo, A, Nielsen, DA, Kakhai, B, et al.Agonist-promoted down-regulation and functional desensitization in two naturally occurring variants of the human serotonin1A receptor. Neuropsychopharmacology. 1997;17:18–26.Google Scholar
97.Andrade, R. Electrophysiology of 5-HT1A receptors in the rat hippocampus and cortex. Drug Dev Res. 1992;26:275–286.Google Scholar
98.Araneda, R, Andrade, R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience. 1991;40:399–412.Google Scholar
99.Ashby, CR, Edwards, E, Wang, RY. Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse. 1994;17:173–181.Google Scholar
100.Blue, ME, Yagaloff, KA, Mamounas, LA, et al.Correspondence between 5-HT2 receptors and serotonergic axons in rat neocortex. Brain Res. 1988;453:315–328.CrossRefGoogle ScholarPubMed
101.Wilson, MA, Molliver, ME. The organization of serotonergic projections to cerebral cortex in primates: regional distribution of axonal terminals. Neuroscience. 1991;44:537–553.Google Scholar
102.Chaouloff, F. Physiopharmacological interactions between stress hormones and central serotonergic system. Brain Res Brain Res Rev. 1993;18:1–32.Google Scholar
103.Lesch, KP, Lerer, B. The 5-HT receptor-G protein-effector system complex in depression: I. Effect of glucocorticoids. J Neural Transm Gen Sect. 1991;84:3–18.Google Scholar
104.Dinan, TG. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Life Sci. 1996;58:1683–1694.Google Scholar
105.Tejani-Butt, SM, Labow, DM. Time course of the effects of adrenalectomy and corticosterone replacement on 5-HT1A receptors and 5-HT uptake sites in the hippocampus and dorsal raphe nucleus of the rat brain: an autoradiographic analysis. Psychopharmacology (Berl). 1994;113:481–486.Google Scholar
106.Graeff, FG, Guimaraes, FS, De Andrade, TGCS, Deakin, JFW. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav. 1996;54:129–141.Google Scholar
107.Beck, SG, Choi, KC, List, TJ, Okuhara, DY, Birnstiel, S. Corticosterone alters 5-HT1A receptor-mediated hyperpolarization in area CA1 hippocampal pyramidal neurons. Neuropsychopharmacology. 1996;14:27–33.Google Scholar
108.Young, AH, Goodwin, GM, Dick, H, Fink, G. Effects of glucocorticoids on 5-HT1A presynaptic function in the mouse. Psychopharmacology. 1994;114:360–364.Google Scholar
109.Przegalinsky, E, Budziszewska, B, Warchol-Kania, A, Blaszczynsaka, E. Stimulation of corticosterone secretion by the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the rat. Pharmacol Biochem Behav. 1989;33:329–334.Google Scholar
110.Koenig, JI, Meltzer, HY, Grudelesky, GA. 5-Hydroxytryptamine1A receptor-mediated effects of buspirone, gepirone and ipsapirone. Pharmacol Biochem Behav. 1988;29:711–715.Google Scholar
111.Kidd, EJ, Haj-Dahmane, S, Jolas, T, et al.New methoxychroman derivatives, 4[N-(5-methoxy-chroman-3-yl)N-propylamino]butyl-8-azaspiro-(4,5)-decane-7,9-dione [(+)-S 20244] and its enantiomers, (+)-S 20499 and (-)-S 20500, with potent agonist properties at central 5-hydroxytryptamine1A receptors. J Pharmacol Exp Ther. 1993;264:863–872.Google Scholar
112.Van Wijngaarden, I, Tulp, MThM, Soudijn, W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990;188:301–312.Google Scholar
113.Borsini, F, Giraldo, E, Monferini, E, et al.BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex. Naunyn-Schmiedebergs Arch Pharmacol. 1995;352:276–282.Google Scholar
114.Khawaja, X, Evans, N, Reilly, Y, et al.Characterisation of the binding of [3H]WAY-100635, a novel 5-hydroxytryptamine1A receptor antagonist, to rat brain. J Neurochem. 1995;64:2716–2726.Google Scholar
115.Middlemiss, DN, Tricklebank, MD. Centrally active 5-HT receptor agonists and antagonists. Neurosci Biobehav Rev. 1992;16:75–82.Google Scholar
116.Briunvels, AT, Palacios, JM, Hoyer, S. Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn-Schmiedebergs Arch Pharmacol. 1993;347:569–582.Google Scholar
117.Tanaka, H, Tatsuno, T, Shimizu, H, et al.Effects of tandospirone on second messenger system and neurotransmitter release in the rat brain. Gen Pharmacol. 1995;26:1765–1772.Google Scholar
118.Jolas, T, Haj-Dahmane, S, Lanfumey, L, et al.Tertatolol is a potent antagonist at pre- and postsynaptic sero-tonin 5-HT1A receptors in the rat brain. Naunyn-Schmiedebergs Arch Pharmacol. 1993;347:453–463.Google Scholar
119.Peglion, JL, Canton, H, Bervoets, K, et al.Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazines. J Med Chem. 1995;38:4044–4055.Google Scholar
120.Sills, MA, Bennett, DA, Lovell, RA, et al.CGS 18102A, a benzopyranopyridine anxiolytic 5-HT1A agonist and 5-HT2 antagonist properties. In Current and Future Trends in Anticonvulsant, Anxiety, and Stroke Therapy. New York:Wiley-Liss, Inc. 1990;469–475.Google Scholar
121.Albinsson, A, Bjork, A, Svartengren, J, et al.Preclinical pharmacology of FG5893: a potential anxiolytic drug with high affinity for both 5-HT1A and 5-HT2A receptors. Eur J Pharmacol. 1994;261:285–294.Google Scholar
122.Uchida, H, Inagawa, K, Tameda, C, Miyauchi, T. Pharmacological profile of (-)HT-90B, a novel 5-HT1A receptor agonist/5-HT2 receptor antagonist. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:1201–1216.Google Scholar
123.Foreman, MM, Fuller, RW, Leander, Det al.Preclinical studies on LY228729: a potent and selective serotonin1A agonist. J Pharmacol Exp Ther. 1993;267:58–71.Google Scholar
124.Johansson, L, Sohn, D, Thorberg, SO, et al.The pharmacology characterization of a novel selective 5-hydroxy-tryptamine1A receptor antagonist, NAD-299. J Pharmacol Exp Ther. 1997;283:216–225.Google Scholar
125.Shen, Y, Monsma, FJ, Metcalf, MA, et al.Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem. 1993;268:18200–18204.Google Scholar
126.Kung, MP, Frederick, D, Mu, M, et al.4-(2′-Methoxy.phenyl)-1-[2′-(n-2″- pyridinyl)-p-iodobenzamido]-ethyl-piperazine ([125I]p-MPPI) as a new selective radioligand of serotonin-1A sites in rat brain: in vitro binding and autoradiographic studies. J Pharmacol Exp Ther. 1995;272:429–437.Google Scholar
127.Millan, MJ, Rivet, JM, Canton, H, et al.S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytyptamine1C/2 receptors. J Pharm Exp Ther. 1992;262:451–463.Google Scholar
128.Kilpatrick, AT, Brown, CM, MacKinnon, AC, et al.The alpha2-adrenoceptor antagonist SKF 104078 has high affinity for 5-HT1A and 5-HT2 receptors. Eur J Pharmacol. 1989;166:315–318.Google Scholar
129.Shimizu, H, Karai, N, Hirose, A. Interaction of SM-3997 with serotoninß receptors in rats brain. Jpn J Pharmacol. 1988;46:311–314.Google Scholar
130.Schoeffter, P, Bobirnac, I, Boddeke, E, Hoyer, D. Inhibition of cAMP accumulation via recombinant human serotonin 5-HT1A receptors: considerations on receptor effector coupling across systems. Neuropharmacology. 1997;36:429–437.Google Scholar
131.Dumuis, A, Sebben, M, Bockaert, J. Pharmacology of 5-hydroxytryptamine1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture. Mol Pharmacol. 1988;33:178–1186.Google Scholar
132.Schoeffter, P, Hoyer, D. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn-Schmiedebergs Arch Pharmacol. 1989;339:675–683.Google Scholar
133.Cornfield, LJ, Nelson, DL, Taylor, EW, Martin, AR. MDL 73005EF: partial agonist at the 5-HT1A receptor negatively linked to adenylate cyclase. Eur J Pharmacol. 1989;173:189–192.Google Scholar
134.Kung, HF, Kung, MP, Clarke, W, et al.A potential 5-HT1A receptor antagonist: p-MPPI. Life Sci. 1994;55:1459–1462.Google Scholar
135.Cornfield, LJ, Lambert, G, Arvidsson, LE, et al.Intrinsic activity of enantiomers of 8-hydroxytry-2-(di-n-propylamino)tetralin and its analogs at 5-hydroxy-tryptamine1A receptors that are negatively coupled to adenylate cyclase. Mol Pharmacol. 1991;39:780–787.Google Scholar
136.Oksenberg, D, Peroutka, SJ. Antagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers. Biochem Pharmacol. 1988;37:3429–3433.Google Scholar
137.Chaput, Y, de Montigny, C. Effects of the 5-hydroxytryptamine1 receptor antagonist, BMY 7378, on 5-hydroxytryptamine neurotransmission: electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther. 1988;246:359–370.Google Scholar
138.Sprouse, JS. Inhibition of the dorsal raphe cell firing by MDL 73005EF, a novel 5-HT1A receptor ligand. Eur J Pharmacol. 1991;201:163–169.Google Scholar
139.Colino, A, Halliwell, JV. 8-OH-DPAT is a strong antagonist of 5-HT action in rat hippocampus. Eur J Pharmacol. 1986;130:151–152.Google Scholar
140.Segal, M, Azmitia, EC, Whitaker-Azmitia, PM. Physiological effects of selective 5-HT1A and 5-HT1B ligands in rat hippocampus: comparison to 5-HT. Brain Res. 1989;502:67–74.Google Scholar
141.Sprouse, JS, Aghajanian, GK. Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology. 1988;27:707–715.Google Scholar
142.VanderMaelen, CP, Matheson, GK, Wilderman, RC, Patterson, LA. Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur J Pharmacol. 1986;129:123–130.Google Scholar
143.Andrade, R, Nicoll, RA. Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus. Naunyn-Schmiedebergs Arch Pharmacol. 1987;336:5–10.Google Scholar
144.Leishman, DJ, Boeijinga, PH, Galvan, M. Differential effects of centrally-active antihypertensive on 5-HT1A receptors in rat dorsolateral septum, rat hippocampus and guinea-pig hippocampus. Br J Pharmacol. 1994;111:318–324.Google Scholar
145.Borsini, F, Ceci, A, Bietti, G, Donetti, A. BIMT 17, a 5-HT1A receptor agonist/5-HT2A receptor antagonist directly activates postsynaptic 5-HT inhibitory responses in the rat cerebral cortex. Naunyn-Schmiedebergs Arch Pharmacol. 1995;352:283–290.Google Scholar
146.Rueter, LE, de Montigny, C, Blier, P. Electrophysiological characterization of the novel 5-HT1A agonist BIMT 17: differential efficacy at pre-vs postsynaptic areas in the rat brain. Soc Neuroscience. 1997;23:435–436.Google Scholar
147.Haj-Dahmane, S, Hamon, M, Lanfumey, L. K+ channel and 5-hydroxytryptamine1A autoreceptor interactions in the rat dorsal raphe nucleus: an in vitro electrophysiological study. Neurosci. 1991;41:495–505.Google Scholar
148.Sprouse, JS, Aghajanian, GK. Electrophysiological responses of serotonergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse. 1987;1:3–9.Google Scholar
149.Martin, KF, Mason, R. Ipsapirone is a partial agonist at 5-hydroxytryptamine1A (5-HT1A) receptors in the rat hippocampus: electrophysiological evidence. Eur J Pharmacol. 1987;141:479–483.Google Scholar
150.Greuel, JM, Glaser, T. The putative 5-HT1A receptor antagonists NAN-190 and BMY 7378 are partial agonists in the rat dorsal raphe nucleus in vitro. Eur J Pharmacol. 1992;211:211–219.Google Scholar
151.Van den Hoof, P, Galvan, M. Electrophysiology of the 5-HT1A ligand MDL 73005EF in the rat hippocampal slice. Eur J Pharmacol. 1991;196:291–298.Google Scholar
152.Ashby, CR, Wang, RY. The interaction of 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: iontophoretic studies. Soc Neurosci. 1992;18:579–584.Google Scholar
153.Hodgkiss, JP, Dawson, IM, Kelly, JS. An intracellular study of the action of NAN-190 on neurons in the dorsal raphe nucleus of the rat. Brain Res. 1992;576:157–161.Google Scholar
154.Bijak, M, Misgeld, U. Effects of serotonin through sero-tonin1A and serotonin4 receptors on inhibition in the guinea-pig dentate gyrus in vitro. Neuroscience. 1997;78:1017–1026.Google Scholar
155.Craven, R, Grahame-Smith, D, Newberry, N. WAY-100635 and GR 127935: effects on 5-hydroxytryptamine-containing neurones. Eur J Pharmacol. 1994;271:R1–3.Google Scholar